Patient usefulness rating
91/100
Conditions
Graves Disease, Thyroid Cancer
Eligibility
Inclusion Criteria: * patients with initial diagnosis of graves disease OR * patients with initial diagnosis of thyroid carcinoma Exclusion Criteria: * contraindications for oral glucose tolerance test * Diabetes mellitus *…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
89/100
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8 +13
Eligibility
Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis * Stage IV melanoma…
AI-generated summary
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
89/100
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer +23
Eligibility
Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and…
AI-generated summary
DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Eastern Cooperative Oncology Group
Patient usefulness rating
87/100
Conditions
Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS +8
Eligibility
Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks…
AI-generated summary
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials is being studied. Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS +9 • Eligibility: Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any…. Goal: The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
87/100
Conditions
Pleuropulmonary Blastoma, Cystic Nephroma, Ovarian Sertoli-Leydig Cell Tumors, Ocular Medulloepithelioma +1
Eligibility
* INCLUSION CRITERIA: All participants who meet the eligibility criteria outlined below will be eligible for inclusion in this study regardless of their race, gender, ethnicity, or age. * Affected individual is…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University of Calgary
Patient usefulness rating
85/100
Conditions
Papillary Thyroid Cancer
Eligibility
Inclusion Criteria: * Age ≥ 18 years * A diagnosis of papillary thyroid cancer based on a fine needle biopsy (FNB) interpreted as a Bethesda V or VI cytology * A diagnosis…
AI-generated summary
This study tests whether the molecular results from a fine needle biopsy (FNB) using Thyroid GuidePx® are the same as results from the larger surgical tissue in people with papillary thyroid cancer. It is for adults with a preoperative diagnosis of papillary thyroid cancer (Bethesda V/VI) or indeterminate nodules (Bethesda III/IV) who are candidates for thyroidectomy. During surgery, an FNB of the dominant tumor will be taken and both the FNB and surgical samples will undergo RNASeq to see if the FNB can reliably classify the cancer. The goal is to find out if the smaller biopsy is sufficiently representative to guide treatment decisions before surgery. Exclusions include history of neck radiation, inability or unwillingness to have a fine needle biopsy or thyroidectomy, final pathology not showing papillary thyroid cancer, or situations with no clear dominant nodule or multiple nodules precluding sampling.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University of Arizona
Patient usefulness rating
84/100
Conditions
Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma +7
Eligibility
Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing the informed consent. 3.…
AI-generated summary
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Saint Petersburg State University, Russia
Patient usefulness rating
84/100
Conditions
Anaplastic Thyroid Cancer
Eligibility
Inclusion Criteria: * immunohistochemically verified anaplastic thyroid cancer that is not eligible to R0-R1 surgery; * age ≥ 18 years; * functional status of ECOG 0-2; * adequate function of internal organs…
AI-generated summary
The study is testing a combination of pembrolizumab and lenvatinib for people with anaplastic thyroid cancer. It is recruiting adults in Russia whose cancer cannot be fully removed by surgery and who have a reasonably good performance status. The trial aims to find out whether this drug combination can effectively treat the cancer and how safe it is, with responses measured using iRECIST criteria. Key exclusions include BRAF V600 mutations without prior targeted therapy, significant bleeding risk or invasion into large vessels, pregnancy, and poor functional status.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
City of Hope Medical Center
Patient usefulness rating
82/100
Conditions
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Eligibility
Inclusion Criteria: * Pathologic (histologic or cytologic) diagnosis of anaplastic thyroid cancer (a diagnosis that is noted to be ?consistent with anaplastic thyroid cancer? with the presence of a thyroid mass is…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
City of Hope Medical Center
Patient usefulness rating
82/100
Conditions
Thyroid Gland Nodule
Eligibility
Inclusion Criteria: * All patients undergoing FNA for thyroid nodule diagnosis. * Any race and ethnicity are eligible for the study. * Patient should have thyroid nodule(s) with indeterminate diagnosis after FNA…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
M.D. Anderson Cancer Center
Patient usefulness rating
82/100
Eligibility
Inclusion Criteria: All adult patients aged 18 years or older with anaplastic thyroid cancer or poorly differentiated thyroid cancer as their clinical and/ or histological diagnosis will be included. Exclusion Criteria: Patients…
AI-generated summary
This study looks at real-world outcomes for adults with anaplastic thyroid cancer (ATC) or poorly differentiated thyroid cancer (PDTC) and compares overall survival for patients treated at MD Anderson Cancer Center versus those treated elsewhere using MD Anderson regimens based on BRAF status and cancer stage. It aims to learn about barriers to accessing treatments in the real world and how patients tolerate and respond to commercially available medications outside of a clinical trial. The study will collect real-world data on patients who can’t participate in traditional trials but are treated with MD Anderson regimens, grouped by stage and BRAF status. Secondary goals include assessing how chemotherapy, immunotherapy, and radiation affect quality of life, and how factors like health insurance and other sociodemographic characteristics influence outcomes. Eligibility requires adults 18+ with ATC or PDTC; those without ATC/PDTC confirmed on tumor tissue are excluded.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
82/100
Conditions
Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer +14
Eligibility
Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor naive in first line:…
AI-generated summary
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Taiwan University Hospital
Patient usefulness rating
82/100
Conditions
Thyroid Cancer, Follicular Thyroid Cancer
Eligibility
Inclusion Criteria: * diagnosed patients with nodular goiter or multinodular goiter, thyroid papillary, follicular and anaplastic thyroid cancer, pre-operation. Exclusion Criteria: * unclearly diagnosed patients with thyroid papillary, follicular and anaplastic thyroid…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Dana-Farber Cancer Institute
Patient usefulness rating
82/100
Eligibility
Inclusion Criteria: * Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s). * Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s)…
AI-generated summary
- This study tests whether inherited genetic factors may raise the risk of thyroid cancer and thyroid nodules by collecting family history and a blood or saliva sample for genetic analysis.
- It is for children with current or past thyroid cancer or nodules, and for adults from families with a high suspicion of hereditary thyroid cancer.
- Researchers aim to learn which gene changes are linked to thyroid cancer and nodules by DNA sequencing and other genetic studies.
- People who cannot give informed consent or complete study materials are excluded.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University Health Network, Toronto
Patient usefulness rating
82/100
Conditions
Thyroid Nodule, Thyroid Cancer
Eligibility
Inclusion Criteria: 1\. Patients with: * Nodule less than or equal to 2cm in size a. Specifically: Bethesda 5/6 * Their age is ≥18 years and ≤100 years * Able to provide…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Patient usefulness rating
81/100
Eligibility
Inclusion Criteria: * Participants voluntarily join the study, sign the informed consent form, and demonstrate good compliance. * Histologically or cytologically confirmed locally advanced or metastatic differentiated thyroid carcinoma (DTC). * Age:…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Beijing Scitech-Mq Pharmaceuticals Limited
Patient usefulness rating
80/100
Conditions
Differentiated Thyroid Carcinoma
Eligibility
Eligibility Minimum Age: 18 Years Maximum Age: Sex: All Gender Based: Accepts Healthy Volunteers: No Criteria: Inclusion Criteria: 1. Age \>= 18 years 2. Life expectancy of twelve weeks or more 3.…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Royal Marsden NHS Foundation Trust
Patient usefulness rating
80/100
Conditions
Differentiated Thyroid Cancer (DTC)
Eligibility
Inclusion Criteria: * Aged over 18 * Both genders * Patients who are diagnosed of low-risk well-differentiated thyroid carcinoma (papillary thyroid carcinoma or follicular carcinoma) with size of 1-4cm. This is either:…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 79
Sponsor
University Medical Center Groningen
Patient usefulness rating
79/100
Conditions
Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine +1
Eligibility
Inclusion Criteria: * Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma) * Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
79/100
Eligibility
Inclusion Criteria: 1. Pathological and clinical diagnosis of thyroid cancer with lymph node metastases. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the…
AI-generated summary
- The trial tests whether a 68Ga-FAPI PET/CT scan can improve preoperative evaluation of thyroid cancer that has spread to the lymph nodes.
- It is for people aged 16 to 80 who have thyroid cancer with lymph node metastases and who can give informed consent.
- All participants will have the 68Ga-FAPI PET/CT before surgery, and the imaging results will be compared to the surgical pathology to see how accurate the scan is.
- Exclusions include serious illnesses, intestinal problems, pregnancy or breastfeeding, and not complying with study procedures.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Royal Marsden NHS Foundation Trust
Patient usefulness rating
79/100
Eligibility
Inclusion Criteria: * Age 18 years or older. (all cohorts) * Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1) * Patients with newly diagnosed resectable locally advanced…
AI-generated summary
This multicentre, recruiting trial tests whether circulating tumor DNA (ctDNA) in blood and tissue analyses can help study advanced thyroid cancers. It will enroll adults with differentiated, medullary, or anaplastic thyroid cancer and collect blood and tumor tissue to look for ctDNA and other molecular changes. The study aims to learn how ctDNA relates to tumor evolution, treatment response, and disease progression to help tailor therapy. Eligibility includes adults 18+ with specific thyroid cancer statuses across cohorts, availability of archival tissue or willingness to biopsy, and consent; key exclusions are recent invasive cancer within the last 5 years (with some exceptions), pregnancy, or illnesses that would interfere with sample collection.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Karolinska University Hospital
Patient usefulness rating
79/100
Conditions
Thyroid Nodule, Thyroid Cancer, Cognitive Decline, Survivorship +1
Eligibility
Inclusion Criteria: * Age \>18 years old, indication for surgery because of a thyroid nodule Bethesda IV-VI * Able to read and understand the Swedish language * Access to desktop computer or…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Icahn School of Medicine at Mount Sinai
Patient usefulness rating
78/100
Eligibility
Inclusion criteria: * Bethesda category III, IV, V or VI following Fine Needle Aspiration; if a patient has a benign tumor following surgery, patient data/ samples will be stored to serve as…
AI-generated summary
This trial tests whether environmental exposures affect thyroid cancer outcomes by using home-collected dried blood samples and a exposure questionnaire to measure chemicals and metabolic changes. It is for adults 18 and older who have a thyroid nodule categorized as Bethesda III–VI after a fine-needle biopsy and who are surgical candidates. The researchers want to learn if these exposures are linked to prognosis, including disease-specific survival, cancer recurrence, and the tumor’s mutational profile. Exclusions include a history of thyroid cancer, those who have already had completion surgery, and pregnant or other vulnerable individuals.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
IRCCS San Raffaele
Patient usefulness rating
77/100
Conditions
Cancer of Thyroid, Vertebral Fracture, Osteoporosis
Eligibility
Inclusion Criteria: * age ≥ 18 years * Histological diagnosis of Thyroid Carcinoma * radiological data from chest x-ray in lateral projection in the preoperative evaluation on which the vertebral morphometry *…
AI-generated summary
- The study tests how common osteo-metabolic complications are in patients with thyroid cancer.
- It is a multicenter, retrospective observational study and will include about 150-200 outpatients from IRCCS San Raffaele Hospital and Spedali Civili of Brescia.
- Researchers will retrospectively collect anonymized clinical, biochemical, and radiological data after informed consent to learn about these complications.
- Eligible participants are adults (18+) with a thyroid cancer diagnosis and preoperative chest X-ray data that include vertebral morphometry; anyone not meeting these criteria is excluded.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 75
Sponsor
University Health Network, Toronto
Patient usefulness rating
75/100
Conditions
Papillary Thyroid Cancer, Papillary Thyroid Carcinoma, Papillary Microcarcinoma of the Thyroid
Eligibility
Inclusion Criteria: * Patients 18 years of age or older. * Newly diagnosed previously surgically untreated papillary thyroid cancer (PTC) or suspicious for PTC on fine needle aspiration biopsy of the thyroid.…
AI-generated summary
This is a prospective, observational, multi-center study of adults with small, low-risk papillary thyroid cancer who choose either active surveillance or immediate thyroid surgery. It aims to describe long-term outcomes and whether the chosen management reaches its goal (avoiding surgery if the cancer doesn’t progress with active surveillance, or cure after surgery). Participants are followed yearly for up to 10 years, with patient-reported outcomes collected yearly for up to 5 years. Key exclusions include metastatic thyroid cancer, prior thyroid surgery, cancer near critical structures with high growth risk, locally advanced disease, poorly differentiated or non-papillary thyroid cancer, pregnancy, or inability to consent or follow up.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 75
Sponsor
University Health Network, Toronto
Patient usefulness rating
75/100
Conditions
Thyroid Cancer Stage I
Eligibility
Inclusion Criteria: 1. Patients 18 years of age or older 2. Newly diagnosed previously untreated papillary thyroid cancer (PTC) (fine needle aspiration biopsy positive for PTC or suspicious for PTC). 3. PTC…
AI-generated summary
This is an observational study that looks at how people with small, low-risk papillary thyroid cancer decide between active surveillance (watchful waiting) and thyroid surgery. It includes adults 18 and older with a new diagnosis confined to the thyroid and a tumor 2 cm or smaller, with no distant metastasis. In part 1, patients are informed about options and choose between active surveillance or surgery; in part 2, those who chose one option are followed to study outcomes, including quality of life and the main focus, decision regret after one year. Exclusions include metastatic cancer, prior thyroid surgery, high-risk tumor location, signs of local invasion, pregnancy, and other serious conditions affecting treatment or follow-up. The study is currently not recruiting.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 72
Sponsor
Providence Health & Services
Patient usefulness rating
72/100
Conditions
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma +3
Eligibility
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Histologically (or cytologically) confirmed diagnosis of metastatic, radioiodine (RAI) refractory, BRAFV600E/M mutant differentiated thyroid cancer…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 71
Patient usefulness rating
71/100
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms +12
Eligibility
Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via local molecular testing, an…
AI-generated summary
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 71
Patient usefulness rating
71/100
Conditions
Solid Tumors, CNS Tumors
Eligibility
Inclusion Criteria: 1. Disease status: * Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 * Phase 2 portion: * Part B: Participants must have…
AI-generated summary
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is being studied. Conditions: Solid Tumors, CNS Tumors • Eligibility: Inclusion Criteria: 1. Disease status: * Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 * Phase 2 portion: * Part…. Goal: This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 70
Sponsor
University of Alabama at Birmingham
Patient usefulness rating
70/100
Conditions
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer +5
Eligibility
Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer; or \[localized (includes in…
AI-generated summary
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health is being studied. Conditions: Breast Cancer, Colorectal Cancer, Endometrial Cancer +6 • Eligibility: Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer;…. Goal: This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Alabama at Birmingham.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 70
Sponsor
Instituto do Cancer do Estado de São Paulo
Patient usefulness rating
70/100
Conditions
Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma +37
Eligibility
Inclusion Criteria 1. Age 18 years or older. 2. Patients with immunohistochemistry for PD-L1 with a combined positive score (CPS) of 10 or higher. 3. Patients with progression or intolerance to already…
AI-generated summary
The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 69
Sponsor
Tata Memorial Hospital
Patient usefulness rating
69/100
Conditions
Thyroid Cancer Stage IV, Radiation Toxicity
Eligibility
Inclusion Criteria: A) All patients of differentiated thyroid cancer (papillary/follicular/poorly differentiated/) who have undergone total/completion thyroidectomy at our institute and having at least two of the following features (listed below) intra-operatively and/or…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 68
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Patient usefulness rating
68/100
Conditions
Thyroid Cancers
Eligibility
Inclusion Criteria: * Age 18- 65 years old, both male and female * Postoperative pathology was papillary thyroid carcinoma * Clinical data integrity Exclusion Criteria: * Postoperative pathology was benign * Clinical…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 67
Sponsor
Salubris Biotherapeutics Inc
Patient usefulness rating
67/100
Conditions
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer +18
Eligibility
Inclusion Criteria: 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits. 3. For Dose Escalation, patients with one of…
AI-generated summary
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is being studied. Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor +19 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits. 3. For Dose Escalation,…. Goal: This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Salubris Biotherapeutics Inc.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 66
Sponsor
Memorial Sloan Kettering Cancer Center
Patient usefulness rating
66/100
Eligibility
Inclusion Criteria: * Age ≥18 years * English speaking * Patients with confirmed thyroid malignancy confirmed by preoperative fine needle biopsy (any stage) planned for surgical excision Exclusion Criteria: * Inability to…
AI-generated summary
This study tests what patients undergoing thyroid cancer surgery expect from their thyroid surgery. It is for adults 18 and older who are English-speaking and have a confirmed thyroid cancer planned for surgical removal. Researchers want to learn how patients’ expectations can help doctors better prepare and inform them about the disease and its treatment. The study is currently not recruiting, and exclusions include non-English speakers, inability to give informed consent due to disability, prior thyroid surgery, and prior thyroid cancer treatments like radioactive iodine or chemotherapy.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 66
Sponsor
Memorial Sloan Kettering Cancer Center
Patient usefulness rating
66/100
Conditions
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
Eligibility
Inclusion Criteria: * Pathological (histologically or cytologically) proven diagnosis of BRAF-V600E mutant ATC (a diagnosis that is noted to be consistent with ATC is acceptable) * Either Metastatic disease or locoregional disease…
AI-generated summary
- The study tests whether adding cemiplimab to the standard drugs dabrafenib and trametinib helps adults with anaplastic thyroid cancer.
- It is for people whose cancer has the BRAF-V600E mutation and is metastatic or not surgically curable, with measurable disease.
- Researchers want to learn if this combination improves cancer control and patient outcomes.
- Key exclusions include prior dabrafenib/trametinib treatment (with limited exceptions), active brain metastases, certain autoimmune conditions or infections, HIV on antiretroviral therapy, and other serious medical issues.
- The study is currently not recruiting.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 66
Sponsor
Memorial Sloan Kettering Cancer Center
Patient usefulness rating
66/100
Eligibility
Inclusion Criteria: * Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants). * Patients should have tumors that are radiographically evident on PET,…
AI-generated summary
- The study tests a new PET imaging agent called 18F-TFB to see if it can predict how thyroid cancer takes up radioactive iodine, possibly faster than current methods.
- It is for adults with thyroid cancer of follicular origin (including papillary types) whose tumors are visible on imaging tests.
- The goal is to learn whether this imaging test can help guide radioactive iodine therapy without interfering with its uptake.
- Key exclusions include pregnancy or breastfeeding, an inability to follow a low-iodine diet, and recent use of iodinated contrast within the last 3 months.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 66
Sponsor
University Hospital, Basel, Switzerland
Patient usefulness rating
66/100
Conditions
Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2, Neuroendocrine Tumor of the Thymus Grade 1 and 2, Neuroendocrine Tumor GEP Grade 1-3
Eligibility
Inclusion Criteria: Phase 0 study * Advanced MTC with elevated levels of calcitonin (\> 100 pg/ml) and/or calcitonin-doubling time \< 24 months before or after total thyroidectomy or * Patients with well…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
65/100
Conditions
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma +17
Eligibility
Inclusion Criteria: * Main Inclusion Criterion: 1\. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations. * Other Inclusion Criteria: 1.…
AI-generated summary
This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
APPROVED_FOR_MARKETINGRating 56
Sponsor
Eli Lilly and Company
Patient usefulness rating
56/100
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer +3
Eligibility
Inclusion Criteria: * Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib * Have progressed or are…
AI-generated summary
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation is being studied. Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer +4 • Eligibility: Inclusion Criteria: * Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib *…. Goal: Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Eli Lilly and Company.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Shanghai Jiao Tong University School of Medicine
Patient usefulness rating
55/100
Conditions
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
Eligibility
Inclusion Criteria: 1. The subjects voluntarily sign the written informed consent form and can comply with the visits and related procedures specified in the protocol; 2. The subjects are 18 years old…
AI-generated summary
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) is being studied. Conditions: Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma +1 • Eligibility: Inclusion Criteria: 1. The subjects voluntarily sign the written informed consent form and can comply with the visits and related procedures specified in the protocol; 2. The subjects…. Goal: Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging. Previous genomic profiling studies showed they presented a number of somatic mutations. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Jiao Tong University School of Medicine.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Rutgers, The State University of New Jersey
Patient usefulness rating
51/100
Conditions
Prostate Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer +5
Eligibility
Inclusion Criteria: * Age ≥ 55 years * Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on ADT/ hormone manipulation, must…
AI-generated summary
Project HERO: Health Empowerment & Recovery Outcomes is being studied. Conditions: Prostate Cancer, Bladder Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: * Age ≥ 55 years * Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on…. Goal: Project HERO is a 12-week study of the efficacy of Body Mind Training (BMT, i.e. Tai Chi and Qigong in this project) for reducing fatigue in male cancer survivors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Rutgers, The State University of New Jersey.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
51/100
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer +72
Eligibility
Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according to a plan determine…
AI-generated summary
The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Novartis Pharmaceuticals
Patient usefulness rating
51/100
Conditions
Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer +1
Eligibility
Inclusion Criteria: * Written informed consent must have been obtained prior to any screening procedures * Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by…
AI-generated summary
Phase I/II Study of PDR001 in Patients With Advanced Malignancies is being studied. Conditions: Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer +2 • Eligibility: Inclusion Criteria: * Written informed consent must have been obtained prior to any screening procedures * Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable…. Goal: The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent to adult patients with solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Novartis Pharmaceuticals.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Ottawa Regional Cancer Centre
Patient usefulness rating
51/100
Conditions
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer +3
Eligibility
DISEASE CHARACTERISTICS: * Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability * Patients with thyroid cancer must have failed…
AI-generated summary
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors is being studied. Conditions: Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer +4 • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability * Patients with thyroid…. Goal: RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ottawa Regional Cancer Centre.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Institutes of Health Clinical Center (CC)
Patient usefulness rating
51/100
Eligibility
DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both of the following criteria…
AI-generated summary
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University of Medicine and Dentistry of New Jersey
Patient usefulness rating
51/100
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer +5
Eligibility
DISEASE CHARACTERISTICS: * Histologically confirmed malignant solid tumor that involves an activated Ras/Raf/MAPK pathway, including the following: * Breast cancer * Prostate cancer * Colon cancer * Pancreatic cancer * Ovarian cancer…
AI-generated summary
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors is being studied. Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignant solid tumor that involves an activated Ras/Raf/MAPK pathway, including the following: * Breast cancer * Prostate cancer * Colon cancer * Pancreatic…. Goal: RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Medicine and Dentistry of New Jersey.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
TransThera Sciences (Nanjing), Inc.
Patient usefulness rating
50/100
Conditions
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer +7
Eligibility
Inclusion Criteria: 1. ≥ 18 years of age 2. Arm A：Histopathological or cytologically documented locally advanced or metastatic and solid tumors（including but not limited to advanced cholangiocarcinoma, small cell lung cancer, HER2-negative…
AI-generated summary
The trial tests TT-00420 (Tinengotinib) as a tablet given alone and in combination for adults with advanced solid tumors. It has three arms: Arm A tests TT-00420 alone in various advanced cancers; Arm B combines TT-00420 with atezolizumab for advanced biliary tract cancer; Arm C combines TT-00420 with nab-paclitaxel for advanced triple-negative breast cancer. The study is a Phase Ib/II, multicenter, open-label trial that aims to find a safe and tolerable dose for the next phase and then evaluate preliminary efficacy in each arm. Eligibility includes adults 18 or older with measurable disease and adequate organ function; key exclusions include pregnancy, active HIV/HBV/HCV infection, significant heart problems or QT prolongation, active brain metastases, and recent systemic anticancer therapy or conflicting medications. Status: COMPLETED. Sponsor: TransThera Sciences (Nanjing), Inc.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Actym Therapeutics, Inc.
Patient usefulness rating
49/100
Eligibility
Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible to receive or refuse…
AI-generated summary
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
49/100
Conditions
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix +123
Eligibility
Inclusion Criteria: * Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use * Patients must have measurable or evaluable disease * The…
AI-generated summary
This study tested the combination of interleukin-12 and trastuzumab in people with HER2/neu-overexpressing cancers that have not responded to prior treatment. It was a Phase I dose-escalation trial to find the highest IL-12 dose that could be given safely with trastuzumab and to assess safety. The trial also looked at immune effects, including tumor gene expression, natural killer cell activity, and serum interferon gamma levels. Participants needed measurable disease from HER2-overexpressing cancer and adequate organ function, with a life expectancy of at least 6 months. Exclusions included brain metastases, significant cardiovascular disease, pregnancy, HIV or hepatitis B infection, recent cancer therapies, and prior treatment with Herceptin; the study is completed.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
47/100
Conditions
Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer +1
Eligibility
Key Inclusion Criteria: * The subject has a histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer…
AI-generated summary
Study of XL281 in Adults With Solid Tumors is being studied. Conditions: Cancer, Non-small-cell Lung Cancer, Colorectal Cancer +2 • Eligibility: Key Inclusion Criteria: * The subject has a histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist…. Goal: The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production. Phase/Status/Sponsor: Unknown phase; COMPLETED; Exelixis.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Fore Biotherapeutics
Patient usefulness rating
46/100
Conditions
Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer +3
Eligibility
Inclusion Criteria: * Age ≥ 18 years * Measurable disease by RECIST 1.1 criteria (solid tumors) * ECOG performance status of 0-2 * Life expectancy ≥ 3 months * Adequate hematologic, hepatic,…
AI-generated summary
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. is being studied. Conditions: Melanoma, Thyroid Cancer, Colorectal Cancer +4 • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Measurable disease by RECIST 1.1 criteria (solid tumors) * ECOG performance status of 0-2 * Life expectancy ≥ 3 months…. Goal: The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors. An additional objective is to identify a Recommended Phase 2 (RP2D) for further evaluation in the Extension Cohorts (Phase IIa portion). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fore Biotherapeutics.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University of Chicago
Patient usefulness rating
45/100
Conditions
Tumors, Neoplasm Metastasis
Eligibility
Inclusion Criteria: * Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Patients with hematologic malignancies…
AI-generated summary
Rapamycin With Grapefruit Juice for Advanced Malignancies is being studied. Conditions: Tumors, Neoplasm Metastasis • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. *…. Goal: The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.